Piper Sandler Maintains Overweight on Pacira BioSciences, Maintains $42 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem maintains an Overweight rating on Pacira BioSciences (NASDAQ:PCRX) with a $42 price target.
July 03, 2024 | 4:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler analyst David Amsellem maintains an Overweight rating on Pacira BioSciences with a $42 price target, indicating confidence in the company's future performance.
The maintained Overweight rating and $42 price target from Piper Sandler suggests a positive outlook for Pacira BioSciences, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100